Pharma Stocks
-
How Xenon’s Phase 3 X-TOLE2 Epilepsy Data and Combo Potential Could Impact Xenon Pharmaceuticals (XENE) Investors
Earlier in August 2026, Xenon Pharmaceuticals announced that it would present topline Phase 3 X-TOLE2 results for azetukalner in focal…
Read More » -
Could Knight Therapeutics (TSX:GUD) Strengthen Its Pharma Strategy?
Highlights Specialty pharma exposure spans Canada and Latin American markets. Product launches and licensing remain central operating focus areas. Capital…
Read More » -
Bearish Momentum Raises Correction Risk as Investor Sentiment Turns Cautious
Introduction Innocan Pharma Corp. (CSE: INNO) is a pharmaceutical technology and consumer wellness company developing drug-delivery technologies alongside commercial wellness…
Read More » -
Schott Pharma stock edges lower as Q3 revenue tops $300 million
Schott Pharma SE (ISIN DE000A3ENQ51) stock is showing modest losses on August 26, 2026, after recent trading on XETRA and…
Read More » -
Stocks to watch: Varun Beverages, Groww, Welspun Corp, HEG, Tata Motors PV | Markets News
Stocks to watch today: Easing crude oil prices are expected to drive gains on Dalal Street on Wednesday, even…
Read More » -
Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?
© Erik S. Lesser / Getty Images The setup around Merck (NYSE:MRK | MRK Price Prediction) shares heading into September…
Read More » -
Should FDA’s Ziihera First-Line Approval in HER2 Gastric Cancer Require Action From Jazz (JAZZ) Investors?
Jazz Pharmaceuticals recently received U.S. FDA approval for two Ziihera (zanidatamab-hrii)-based regimens as first-line treatments for adults with unresectable locally…
Read More » -
Sensex, Nifty End Higher as Healthcare, Pharma and PSU Bank Stocks Gain
MUMBAI — Indian benchmark indices recovered from early losses to end Tuesday’s session higher, supported by gains in healthcare, pharmaceutical…
Read More » -
Insider Sellers Might Regret Selling Moberg Pharma Shares at a Lower Price Than Current Market Value
Moberg Pharma AB (publ)’s (STO:MOB) value has fallen 14% in the last week, but insiders who sold kr5.2m worth of…
Read More » -
Merck (MRK) Stock May Be 35% Undervalued After Cancer Vaccine Data
Merck stock has delivered a strong 130.2% return over the past 5 years, yet its valuation picture is split, with…
Read More »